Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases

Patients with melanoma brain metastases have a poor prognosis and historically have been excluded from clinical trials. The Expanded Access Program (EAP) provided an opportunity to evaluate the feasibility of ipilimumab (3 mg/kg every 3 weeks for four doses) in patients with stage 3 (unresectable) o...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: Queirolo, Paola, Spagnolo, Francesco, Ascierto, Paolo Antonio, Simeone, Ester, Marchetti, Paolo, Scoppola, Alessandro, Del Vecchio, Michele, Di Guardo, Lorenza, Maio, Michele, Di Giacomo, Anna Maria, Antonuzzo, Andrea, Cognetti, Francesco, Ferraresi, Virginia, Ridolfi, Laura, Guidoboni, Massimo, Guida, Michele, Pigozzo, Jacopo, Chiarion Sileni, Vanna
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Springer US 2014
Onderwerpen:
Clinical Study
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4023079/
https://ncbi.nlm.nih.gov/pubmed/24532241
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-014-1400-y
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items